In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:

• PARP inhibitors combined with androgen receptors
• Phase III trials of PARP inhibitors with androgen receptor–directed therapy
• PARP inhibitors combined with immunotherapy
• PARP inhibitors and DNA damaging agents

Presenters:

Karim Fizazi, MD, PhD
Full Professor
Cancer Medicine
Institut Gustave Roussey
Villejuif, France

Joaquin Mateo, MD, PhD
Attending Physician
Medical Oncology
Vall d’Hebron University Hospital,
Barcelona, Spain

Content is part of an online program supported by an educational grant from Pfizer Inc.

Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:
https://bit.ly/3spLzqa

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.